WSA
CLLS

Wall Street Associates’s Cellectis CLLS Stock Holding History

Wall Street Associates’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-20,000
Closed -$527K – 304
2015
Q3 		$527K Hold
20,000
– – 0.1% 216
2015
Q2 		$722K Hold
20,000
– – 0.07% 238
2015
Q1 		$692K Buy
+20,000
New +$726K 0.07% 242

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wall Street Associates's CLLS Position: Q4 2015 in Review

Wall Street Associates sold out of Cellectis (CLLS) in Q4 2015, closing a stake of 20,000 shares — an estimated $527K sold.

Wall Street Associates first reported a position in CLLS in Q1 2015 and held it in 3 quarters. The position peaked at $722K in Q2 2015. 48 funds tracked by Wall St. Rank hold CLLS as of Q4 2015.

  • Wall Street Associates reported no remaining Cellectis position as of Q4 2015 after selling out during the quarter.
  • Wall Street Associates sold 20,000 Cellectis shares in Q4 2015, an estimated $527K.
  • Wall Street Associates first reported a position in Cellectis in Q1 2015 and held it in 3 quarters.
  • Wall Street Associates's Cellectis position peaked at $722K in Q2 2015.
  • 48 funds tracked by Wall St. Rank held Cellectis as of Q4 2015.

Based on Wall Street Associates's 13F filing for Q4 2015, filed 11 Feb 2016.